• Türkçe
    • English
  • English 
    • Türkçe
    • English
  • Login
View Item 
  •   Home
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • View Item
  •   Home
  • Avesis
  • Dokümanı Olmayanlar
  • Makale
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: Single center experience from Turkey

Date
2007
Author
Dizdar, Yavuz
Darendeliler, Emin
Bilgic, Bilge
Sakar, Burak
Basaran, Mert
Onat, Haluk
Bavbek, Sevil
Ozger, Harzem
Basaran, Gul Atalay
Agaoglu, Fulya Yaman
Ustuner, Zeki
Metadata
Show full item record
Abstract
USTUNER, Z., BASARAN, M., DIZDAR, Y., AGAOGLu, F.Y., BILGic, B., SAKAR, B., BASARAN, G.A., DARENDELILER, E., OZGER, H., ONAT, H. and BAVBEK, S. Clinical Outcome of Rhadomyosarcoma in Adolescent and Adult Patients: Single Center Experience from Turkey. Tohoku J. Exp. Med., 2007, 213 (3), 221-229 - Rhabdomyosarcoma (RMS) is rare disease in adults (age >= 16 years). The data from randomized prospective trials are scarce; the clinical outcome of these patients seems poor with the currently available treatment strategies. In this study, we report a single institution's experience in the treatment of adult RMS. We reviewed the medical records of patients with RMS who were >= 16 years and have been treated in our institution between 1988 and 2003 retrospectively. We analyzed the survival outcome of these patients and the prognostic impact of clinical/ pathological factors on their survival. In total, 23 patients with RMS were identified. Median age was 26 years (range, 16-72 years). Majority of patients were male (n: 17, 73.9%), and had large tumors ( >= 5 cm, n: 13, 56.5%), localized disease (NO, MO, n: 12, 52.2%), and embryonal histology (n: 10, 43.5%). Median overall survival was 31.3 months, and the 3-year progress ion-free survival and overall survival rates were 19.9% and 34.94%, respectively. Patients with smaller tumors (< 5 cm) (p < 0.04), local disease (p < 0.01), and normal lactic dehydrogenase (LDH) level (p < 0.01) at the time of diagnosis were found to have better survival outcome. The tumor size, serum LDH level, and metastatic disease at the time of diagnosis are potential predictors of outcome in patients with adult RMS. Adult RMS is an aggressive disease with poor survival despite treatment. The data from prospective, randomized multicenter trials are necessary in order to improve the clinical outcome of adult RMS patients. - rhabdomyosarcoma; adult; lactic dehydrogenase; survival; adolescent (0 2007 Tohoku University Medical Press
URI
http://hdl.handle.net/20.500.12627/145537
https://doi.org/10.1620/tjem.213.221
Collections
  • Makale [92796]

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 


Hakkımızda
Açık Erişim PolitikasıVeri Giriş Rehberleriİletişim
sherpa/romeo
Dergi Adı/ISSN || Yayıncı

Exact phrase only All keywords Any

BaşlıkbaşlayaniçerenISSN

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypesThis CollectionBy Issue DateAuthorsTitlesSubjectsTypes

My Account

LoginRegister

Creative Commons Lisansı

İstanbul Üniversitesi Akademik Arşiv Sistemi (ilgili içerikte aksi belirtilmediği sürece) Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV